<DOC>
	<DOC>NCT00443482</DOC>
	<brief_summary>This study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new inhalation device (Concept1) are equivalent to the corresponding dose of formoterol delivered by the Aerolizer device in terms of efficacy, in patients with persistent asthma.</brief_summary>
	<brief_title>Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>History of asthma attacks Forced expiratory volume in 1 second (measure of how well the lungs are working) is greater than 60% of the predicted value Asthma is not stable: patients were admitted to hospital or received emergency room treatment Patients whose asthma drugs need changing within the month prior to the start of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>adults</keyword>
	<keyword>B2 agonist</keyword>
	<keyword>formoterol</keyword>
</DOC>